Clozapine-Induced QEEG Changes Correlate with Clinical Response in Schizophrenic Patients: a Prospective, Longitudinal Study

 

 Buy Article Permissions and Reprints

Background: The changes of theta activity (3.5-7 Hz) in the quantitative electroencephalography (QEEG) and serum clozapine levels and their correlation with clinical response, measured by the Positive and Negative Syndrome Rating Scale (PANSS) for schizophrenia, were examined prospectively in 16 patients suffering from schizophrenia during 18 weeks of clozapine (CLO) treatment. Methods: Evaluations were performed on five occasions: before the initiation of CLO treatment at baseline and after 1, 3, 10, and 18 weeks of treatment. Doses of CLO starting from 50 mg/day were determined on the basis of clinical response. In the PANSS subscales for positive and negative symptoms, a significant (P < 0.05) improvement was observed after the first week, and in the subscale for general symptoms, improvement was seen after three weeks of treatment with CLO. A significant increase in theta power (P < 0.01) was found after three weeks of CLO treatment in the electrodes over the fronto-central scalp area, most distinctly in the midline. Results: After three weeks we observed significant inverse correlations between the theta power increase and the changes in PANSS subscales for negative (P < 0.01) and positive (P < 0.05) symptoms, and after 10 weeks, between the theta power increase and the change in PANSS subscales for general (P < 0.05) and positive (P < 0.05) symptoms. After 18 weeks a trend of inverse correlation between the PANSS subscales for general and negative symptoms and the right and midline theta power increase was observed, but not with regard to positive symptoms. There were trends, but no significant correlations, between CLO treatment response and serum CLO levels. Conclusions: These findings indicate that the change in the theta frequency in QEEG and particularly in the midline electrodes over the fronto-central scalp area might be a more sensitive indicator for the evaluation of CLO treatment adequacy than the serum CLO level.

References

• 1 Adler G, Grieshaber S, Faude V, Thebaldi B, Dressing H. Clozapine in patients with chronic schizophrenia: serum level, EEG and memory performance.  Pharmacopsychiatry. 2002;  35 190-194
  Article in Thieme ConnectPubMedGoogle Scholar
• 2 Breier A, Buchanan R W, Kirkpatrick B, Davis O R, Irish D, Summerfelt A, Carpenter W T. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.  Am J Psychiatr. 1994;  151 20-26
  PubMedGoogle Scholar
• 3 Centorrino F, Price B H, Tuttle M, Bahk W -M, Hennen J, Albert M J, Baldessarini R J. EEG abnormalities during treatment with typical and atypical antipsychotics.  Am J Psychiatr. 2002;  159 109-115
  PubMedGoogle Scholar
• 4 Czobor P, Volavka J. Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve.  Psychiatr Res. 1992;  42 129-144
  CrossrefPubMedGoogle Scholar
• 5 Ford M R, Goethe J W, Dekker D K. EEG coherence and power in the discrimination of psychiatric disorders and medication effects.  Biol Psychiatr. 1986;  21 1175-1188
  CrossrefPubMedGoogle Scholar
• 6 Galderisi S, Mucci A, Bucci P, Mignone M L, Maj M. Multilead quantitative EEG profile of clozapine in resting and vigilance-controlled conditions.  Psychiatr Res (Neuroimaging). 1996;  67 113-122
  PubMedGoogle Scholar
• 7 Guenther W, Baghai T, Naber D, Spatz R and Hippius H. EEG alterations and seizures during treatment with clozapine. A retrospective study of 283 patients.  Pharmacopsychiatry. 1993;  26 69-74
  PubMedGoogle Scholar
• 8 Haring C, Neudorfer C, Schwitzer J, Hummer M, Saria A, Hinterhuber H, Fleischhacker W W. EEG alterations in patients treated with clozapine in relation to plasma levels.  Psychopharmacology. 1994;  114 97-100
  PubMedGoogle Scholar
• 9 Horáček J. Novel antipsychotics and extrapyramidal side effects. Theory and reality.  Pharmacopsychiatry. 2000;  33 (Supplement) 34-42
  Article in Thieme ConnectPubMedGoogle Scholar
• 10 Hughes J R, John E R. Conventional and quantitative electroencephalography in psychiatry.  J Neuropsychiat Clin Neurosci. 1999;  11 190-208
  PubMedGoogle Scholar
• 11 John E R, Prichep L S, Alper K R, Mas F G, Cancro R, Easton P, Sverdlov L. Quantitative electrophysiological characteristics and subtyping of schizophrenia.  Biol Psychiatr. 1994;  36 801-826
  CrossrefPubMedGoogle Scholar
• 12 Joutsiniemi S L, Gross A, Appelberg B. Marked clozapine-induced slowing of EEG background over frontal, central, and parietal scalp areas in schizophrenic patients.  J Clin Neurophysiol. 2001;  18 9-13
  PubMedGoogle Scholar
• 13 Kay S, Fiszbein A, Opler L. The Positive and Negative Syndrome Rating Scale (PANSS) for schizophrenia.  Schizophr Bull. 1987;  13 261-276
  CrossrefPubMedGoogle Scholar
• 14 Knott V, Labelle A, Jones B, Mahoney C. EEG hemispheric asymmetry as a predictor and correlate of short-term response to clozapine treatment in schizophrenia.  Clin Electroencephalography. 2000;  31 145-152
  PubMedGoogle Scholar
• 15 Knott V, Labelle A, Jones B, Mahoney C. Quantitative EEG in schizophrenia and in response to acute and chronic clozapine treatment.  Schizophr Res. 2001;  50 41-53
  CrossrefPubMedGoogle Scholar
• 16 Koenig T, Lehmann D, Saito N, Kuginuki T, Kinoshita T, Koukkou M. Decreased functional connectivity of EEG theta-frequency activity in first-episode, neuroleptic-naive patients with schizophrenia: preliminary results.  Schizophr Res. 2001;  50 55-60
  CrossrefPubMedGoogle Scholar
• 17 Meltzer H Y. Dimensions of outcome with clozapine.  Br J Psychiatr. 1992;  160 (Suppl. 17) 46-53
  PubMedGoogle Scholar
• 18 Risby E D, Morgan B V, Nguyen C M, Epstein C M, Jewart R D, Lewine RL and Risch S C. The incidence of clozapine-induced EEG abnormalities.  Schizophr Res. 1993;  9 248
  PubMedGoogle Scholar
• 19 Risby E D, Epstein C M, Jewart R D, Nguyen B V, Morgan W N, Riscch S C, Thrivikraman K V, Lewine R L. Clozapine-induced EEG abnormalities and clinical response to clozapine.  J Neuropsychiat Clin Neurosci. 1995;  7 466-470
  PubMedGoogle Scholar
• 20 Saletu B, Grünberger J, Linzmayer L and Anderer P. Comparative placebo-controlled pharmaco-dynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry.  Pharmacopsychiatry. 1987;  20 2-27
  PubMedGoogle Scholar
• 21 Schuld A, Kühn M Haack M, Kraus T, Hinze-Selch D, Lechner C, Pollmächer T. A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia.  Pharmacopsychiatry. 2000;  33 109-111
  Article in Thieme ConnectPubMedGoogle Scholar
• 22 Small J G, Milstein V, Small I F, Miller M J, Kellams JJ and Corsanro C J. Computerized EEG profiles of haloperidol, chlorpromazine, clozapine and placebo in treatment resistant schizophrenia.  Clin Electroencephalography. 1987;  18 124-135
  PubMedGoogle Scholar
• 23 Tiihonen J, Nousiainen U, Hakola P, Leinonen E, Tuunainen A, Mervaala E and Paanila J. EEG Abnormalities associated with clozapine treatment.  Am J Psychiatr. 1991;  148 1406
  PubMedGoogle Scholar
• 24 Williamson P, Mamelak M. Frontal spectral EEG findings in acutely ill schizophrenics.  Biol Psychiatr. 1987;  22 1021-1024
  CrossrefPubMedGoogle Scholar

Björn Appelberg

Helsinki University Central Hospital

Department of Psychiatry

Lapinlahdentie

00180 Helsinki

Finland

Phone: +358-9-47163700, Mobile: +358 40 548 2332

Fax: +358-9-471 63815

Email: bjorn.appelberg@hus.fi

Email: andres.gross@luukku.com